Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7546731 | 0.90 | LMNA (0.65) | MAPTHDAC8LMNAF2ALDH1A1 | |
| SCHEMBL29074431 | 0.86 | MAPT (0.60) | MAPTHDAC8LMNAF2ALDH1A1 | |
| SCHEMBL28230005 | 0.82 | MAPT (0.56) | MAPTHDAC8LMNAALDH1A1TSHR | |
| SCHEMBL7651665 | 0.82 | MAPT (0.56) | MAPTHDAC8LMNAALDH1A1TSHR | |
| SCHEMBL212175 | 0.82 | TSHR (0.61) | MAPTHDAC8LMNAALDH1A1TSHR | |
| SCHEMBL11281802 | 0.79 | NPC1 (0.56) | MAPTHDAC8LMNAALDH1A1TSHR | |
| SCHEMBL28479127 | 0.79 | MAPT (0.52) | MAPTHDAC8LMNAALDH1A1TSHR | |
| SCHEMBL7325258 | 0.79 | MAPT (0.52) | MAPTHDAC8LMNAALDH1A1TSHR | |
| SCHEMBL943555 | 0.79 | HSD17B10 (0.63) | MAPTHDAC8LMNAALDH1A1TSHR | |
| SCHEMBL1821914 | 0.77 | MAPT (0.68) | MAPTHDAC8ALDH1A1TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200439-B1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160008336-A1 | HDAC INHIBITORS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| US-8455688-B2 | HDAC inhibitors | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120178783-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8143445-B2 | HDAC inhibitors | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| EP-2200439-A1 | HDAC INHIBITORS | Lixte Biotechnology, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090143445-A1 | HDAC Inhibitors | JOHN P. WHITE, ESQ | 2009-06-04 | — | — | US | disclosed |
| WO-2009045440-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20050261298-A1 | Methods of treating conditions associated with an Edg-7 receptor | MANIV ENERGY CAPITAL | 2005-11-24 | — | — | US | disclosed |
| EP-1513522-A2 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR | SRI INTERNATIONAL (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040167165-A1 | Methods of treating conditions associated with an Edg-7 receptor | MANIV ENERGY CAPITAL | 2004-08-26 | — | — | US | disclosed |
| WO-2003062392-A2 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR | CERETEK LLC (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008336-A1 | HDAC INHIBITORS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY | HDAC5, HDAC1, HDAC4 | MAPT 501/4885HDAC8 10/4885LMNA 2220/4885 |
| US-20120178783-A1 | HDAC INHIBITORS | HDAC3, HDAC4, HDAC7 | MAPT 4418/4885HDAC8 6/4885LMNA 2276/4885 |
| US-20040167165-A1 | Methods of treating conditions associated with an Edg-7 receptor | EDNRA, EDNRB, ESRRG | MAPT 4353/4885HDAC8 1311/4885LMNA 3806/4885 |
| US-20050261298-A1 | Methods of treating conditions associated with an Edg-7 receptor | EDNRA, EDNRB, ESRRG | MAPT 4353/4885HDAC8 1311/4885LMNA 3806/4885 |
| US-20090143445-A1 | HDAC Inhibitors | HDAC3, HDAC7, HDAC4 | MAPT 4407/4885HDAC8 5/4885LMNA 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.